帕博利珠单抗对比安慰剂作为已切除IIB或IIC期黑色素瘤辅助治疗的长期随访、交叉及再挑战:III期KEYNOTE-716研究
KEYNOTE-716研究事后4年分析显示,在已切除IIB/IIC期黑色素瘤患者(n=976)中,帕博利珠单抗对比安慰剂继续延长无复发生存期(HR 0.62)和远处转移无生存期(HR 0.59),并在交叉或再挑战患者中观察到抗肿瘤活性,未发现新的安全性信号。
要点
- 中位随访52.8个月,帕博利珠单抗对比安慰剂RFS的HR为0.62,DMFS的HR为0.59。
- 48个月RFS率帕博利珠单抗71.3% vs 安慰剂58.3%,DMFS率81.0% vs 70.1%。
- 交叉或再挑战帕博利珠单抗的患者中观察到抗肿瘤活性,未发现新的安全性信号。
核心结论
- 随访超过4年,帕博利珠单抗继续延长已切除IIB/IIC期黑色素瘤患者的RFS和DMFS,并在交叉至帕博利珠单抗的患者中具有抗肿瘤活性。
研究设计与样本
- III期KEYNOTE-716研究的事后4年分析,患者按1:1随机分配至帕博利珠单抗200 mg或安慰剂静脉给药每3周一次(第1部分),n=976。
- RFS为主要终点,DMFS为次要终点;安慰剂组复发或帕博利珠单抗17周期后复发的患者可交叉至或再挑战帕博利珠单抗(第2部分)。
主要发现
- 中位随访52.8个月(范围39.4-64.8),RFS的HR为0.62(95%CI 0.50-0.78),DMFS的HR为0.59(95%CI 0.45-0.77),均 favoring 帕博利珠单抗。
- 48个月时,帕博利珠单抗组RFS率为71.3%,安慰剂组为58.3%;DMFS率分别为81.0%和70.1%。
- PRFS2的HR为0.75(95%CI 0.56-1.01);48个月PRFS2率帕博利珠单抗组为82.5%,安慰剂组为76.7%。
- 交叉人群中位随访36.9个月;可切除疾病患者(n=41)中位RFS未达到(NR;95%CI 16.8-NR;48个月RFS率50.6%),不可切除疾病患者(n=30)中位PFS为22.0个月(95%CI 4.5-NR)。
- 再挑战患者中位随访21.9个月;可切除疾病患者(n=6)均无复发,不可切除疾病患者(n=3)中1例最佳疗效为疾病稳定;未观察到新的安全性信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB/IIC melanoma in KEYNOTE-716. Results of a post hoc 4-year analysis are reported, including progression/recurrence-free survival 2 (PRFS2). METHODS: Patients were randomly assigned 1:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks (part 1). RFS was the primary end point; DMFS was secondary. Patients with recurrence following placebo or 17 cycles of pembrolizumab could cross over to or be rechallenged with pembrolizumab (part 2). RESULTS: Median follow-up (n = 976) was 52.8 months (range, 39.4-64.8). RFS (HR, 0.62 [95 % CI, 0.50-0.78]) and DMFS (HR, 0.59 [0.45-0.77]) favored pembrolizumab. At 48 months, RFS rates were 71.3 % for pembrolizumab and 58.3 % for placebo, and DMFS rates were 81.0 % and 70.1 %, respectively. The HR for PRFS2 was 0.75 (95 % CI, 0.56-1.01); 48-month PRFS2 rates were 82.5 % for pembrolizumab and 76.7 % for placebo. In the crossover population, median follow-up was 36.9 months; median RFS was not reached (NR; 95 % CI, 16.8-NR; 48-month RFS, 50.6 %) in patients with resectable disease (n = 41) and median progression-free survival was 22.0 months (4.5-NR) in patients with unresectable disease (n = 30). Among patients rechallenged, median follow-up was 21.9 months; none with resectable disease had recurrence (n = 6) and 1 with unresectable disease had best response of stable disease (n = 3). No new safety signals were observed. CONCLUSIONS: With > 4 years follow-up, pembrolizumab continued to prolong RFS and DMFS and had antitumor activity in patients who crossed over to pembrolizumab. TRIAL REGISTRATION: NCT03553836.
引用
- Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025. PMID: 40198940. doi:10.1016/j.ejca.2025.115381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。